NICE issues damning rejection of Celgene's Abraxane
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance rejecting Celgene's pancreatic cancer drug Abraxane (protein-bound paclitaxel) with some damning criticism of the drug's price, effectiveness and safety.